Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23590077 | 0.90 | DHODH (0.71) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL29617664 | 0.90 | DHODH (0.71) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23590222 | 0.89 | PLA2G2A (0.67) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL26074491 | 0.89 | MCL1 (0.45) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23590055 | 0.88 | DHODH (0.50) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23590211 | 0.88 | DHODH (0.56) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL29959049 | 0.86 | DHODH (0.59) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23578600 | 0.86 | DHODH (0.59) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23590216 | 0.86 | DHODH (0.54) | DHODHMEN1KMT2APLA2G2AALDH1A1 | |
| SCHEMBL23590120 | 0.86 | DHODH (0.79) | DHODHMEN1KMT2APLA2G2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023278778-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021133831-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134045-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885MEN1 2373/4885KMT2A 1314/4885 |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DDO, DLD | DHODH 1/4885MEN1 1960/4885KMT2A 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.